Literature DB >> 28334722

Even a Moderate Fluid Removal Rate during Individualised Haemodialysis Session Times Is Associated with Decreased Patient Survival.

Charles Chazot1, Cyril Vo-Van, Christie Lorriaux, Patrik Deleaval, Brice Mayor, Jean-Marc Hurot, Guillaume Jean.   

Abstract

BACKGROUND: Several studies report that fluid removal rate (FRR) above 10-13 mL/h/kg is associated with increased mortality in haemodialysis (HD) patients. AIM: The aims of this study are to assess the influence of moderate FRR on survival in a cohort of prevalent dialysis patients with various dialysis session times and to challenge the FRR thresholds associated with increased mortality risk reported previously.
METHODS: Interdialytic weight gain (IDWG) and FRR (calculated from ultrafiltration [UF], target weight, and session time prescriptions) were studied in 190 prevalent dialysis patients (female: 42%, mean age: 69.5 years, median vintage: 40.2 months, diabetes: 34.7%, loop diuretic prescription: 5.8%) and averaged during the final quarter of 2010. Patient survival was analysed using Kaplan-Meier and Cox-multivariate analyses.
RESULTS: The median IDWG, median session time, and median FRR were 2.33 kg (-0.54-4.57), 5.0 h (3.9-8.0 h), 6.8 mL/h/kg (1.3-16.7), respectively, and FRR was ≥10 mL/h/kg in 11.6% of the patients. The Kaplan-Meier analysis showed decreased patient survival when the FRR was above the median (6.8 mL/h/kg; p = 0.012). The FRR was found to be independently associated with increased mortality (hazard ratio 1.15 [95% CI 1.02-1.29]; p = 0.027) using stepwise Cox proportional hazard regression analysis, including age, vintage, gender, body mass index (BMI), serum albumin level, β2-microglobulin level, cardiovascular and diabetes history, and session time. Online haemodiafiltration did not change this result. The role of residual renal function was unlikely because 74% of the patients had a vintage of >18 months, a minority (5.8%) were prescribed loop diuretics (a surrogate of significant urine output) and β2-microglobulin level was not different in patients who were below or above the FRR median.
CONCLUSION: We concluded that the FRR threshold above which there is an increased mortality is lower than what has been reported (7.8 mL/h/kg). It raises the question of the hazard of fluid removal and intermittence of standard HD.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Fluid removal rate; Haemodialysis; Outcomes; Residual renal function; Survival; Ultrafiltration

Mesh:

Year:  2017        PMID: 28334722     DOI: 10.1159/000464346

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  5 in total

1.  Soft Target Weight: Theory and Simulation of a Novel Haemodialysis Protocol Which Reduces Excessive Ultrafiltration.

Authors:  Damien Ashby; Richard Corbett; Neill Duncan
Journal:  Nephron       Date:  2021-11-16       Impact factor: 2.847

2.  Home hemodialysis treatment and outcomes: retrospective analysis of the Knowledge to Improve Home Dialysis Network in Europe (KIHDNEy) cohort.

Authors:  Shashidhar Cherukuri; Maria Bajo; Giacomo Colussi; Roberto Corciulo; Hafedh Fessi; Maxence Ficheux; Maria Slon; Eric Weinhandl; Natalie Borman
Journal:  BMC Nephrol       Date:  2018-10-11       Impact factor: 2.388

3.  Sodium, volume and pressure control in haemodialysis patients for improved cardiovascular outcomes.

Authors:  Jule Pinter; Charles Chazot; Stefano Stuard; Ulrich Moissl; Bernard Canaud
Journal:  Nephrol Dial Transplant       Date:  2020-03-01       Impact factor: 5.992

4.  Ultrafiltration rate and incident atrial fibrillation among older individuals initiating hemodialysis.

Authors:  Jennifer E Flythe; Sai Liu; Maria E Montez-Rath; Wolfgang C Winkelmayer; Tara I Chang
Journal:  Nephrol Dial Transplant       Date:  2021-11-09       Impact factor: 7.186

5.  Fluid and hemodynamic management in hemodialysis patients: challenges and opportunities.

Authors:  Bernard Canaud; Charles Chazot; Jeroen Koomans; Allan Collins
Journal:  J Bras Nefrol       Date:  2019 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.